Aligos Therapeutics Inc 将获2500万美元首付款及最高4.2亿美元里程碑款项加分层特许权使用费

美股速递04-16

生物制药公司Aligos Therapeutics Inc（ALGS）宣布达成一项重大合作协议，公司将获得2500万美元的预付款。根据协议条款，未来还有望获得总额最高达4.2亿美元的里程碑付款，并附加分层结构的特许权使用费安排。

这笔交易凸显了市场对Aligos Therapeutics研发管线的认可。分层特许权使用费机制意味着公司未来收益将与产品商业化表现直接挂钩，随着销售额增长， royalty 比例将逐步提升。

此次合作将为Aligos Therapeutics提供重要资金支持，加速其创新疗法的研发进程。里程碑付款将分阶段触发，与研发进展和监管审批等关键节点紧密关联。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1174430401?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-04-16 18:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174430401","market":"us","top_or_hot":-1,"title":"Aligos Therapeutics Inc 将获2500万美元首付款及最高4.2亿美元里程碑款项加分层特许权使用费","media":"美股速递","content":"<p>生物制药公司Aligos Therapeutics Inc（ALGS）宣布达成一项重大合作协议，公司将获得2500万美元的预付款。根据协议条款，未来还有望获得总额最高达4.2亿美元的里程碑付款，并附加分层结构的特许权使用费安排。</p>\n<p>这笔交易凸显了市场对Aligos Therapeutics研发管线的认可。分层特许权使用费机制意味着公司未来收益将与产品商业化表现直接挂钩，随着销售额增长， royalty 比例将逐步提升。</p>\n<p>此次合作将为Aligos Therapeutics提供重要资金支持，加速其创新疗法的研发进程。里程碑付款将分阶段触发，与研发进展和监管审批等关键节点紧密关联。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aligos Therapeutics Inc 将获2500万美元首付款及最高4.2亿美元里程碑款项加分层特许权使用费</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAligos Therapeutics Inc 将获2500万美元首付款及最高4.2亿美元里程碑款项加分层特许权使用费\n</h2>\n\n<h4 class=\"meta\">\n\n2026-04-16 18:04 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>生物制药公司Aligos Therapeutics Inc（ALGS）宣布达成一项重大合作协议，公司将获得2500万美元的预付款。根据协议条款，未来还有望获得总额最高达4.2亿美元的里程碑付款，并附加分层结构的特许权使用费安排。\n这笔交易凸显了市场对Aligos Therapeutics研发管线的认可。分层特许权使用费机制意味着公司未来收益将与产品商业化表现直接挂钩，随着销售额增长， ...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALGS","symbol_name":"Aligos Therapeutics, Inc.","start_time":0,"source_url":"","article_id":"1174430401","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174430401","pubTimestamp":1776333864,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"生物制药公司Aligos Therapeutics Inc（ALGS）宣布达成一项重大合作协议，公司将获得2500万美元的预付款。根据协议条款，未来还有望获得总额最高达4.2亿美元的里程碑付款，并附加分层结构的特许权使用费安排。\n这笔交易凸显了市场对Aligos Therapeutics研发管线的认可。分层特许权使用费机制意味着公司未来收益将与产品商业化表现直接挂钩，随着销售额增长， royalty 比例将逐步提升。\n此次合作将为Aligos Therapeutics提供重要资金支持，加速其创新疗法的研发进程。里程碑付款将分阶段触发，与研发进展和监管审批等关键节点紧密关联。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"ALGS":"Aligos Therapeutics, Inc.","BK4139":"生物科技","BK4505":"高瓴资本持仓"},"translate_title":"Aligos Therapeutics Inc to receive $25 million down payment and up to $420 million milestone payment plus tiered royalties","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALGS":1},"content_text":"生物制药公司Aligos Therapeutics Inc（ALGS）宣布达成一项重大合作协议，公司将获得2500万美元的预付款。根据协议条款，未来还有望获得总额最高达4.2亿美元的里程碑付款，并附加分层结构的特许权使用费安排。\n这笔交易凸显了市场对Aligos Therapeutics研发管线的认可。分层特许权使用费机制意味着公司未来收益将与产品商业化表现直接挂钩，随着销售额增长， royalty 比例将逐步提升。\n此次合作将为Aligos Therapeutics提供重要资金支持，加速其创新疗法的研发进程。里程碑付款将分阶段触发，与研发进展和监管审批等关键节点紧密关联。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1174430401","isCrawlerRequest":true}